Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).

被引：32
|
作者：
Appleman, Leonard Joseph
Puligandla, Maneka
Pal, Sumanta K.
Harris, Wayne
Agarwal, Neeraj
Costello, Brian Addis
Ryan, Christopher W.
Pins, Michael
Kolesar, Jill
Vaena, Daniel A.
Parikh, Rahul Atul
Hashmi, Mehmood
Dutcher, Janice P.
DiPaola, Robert S.
Haas, Naomi B.
Carducci, Michael Anthony
机构：
[1] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA
[4] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA USA
[5] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[6] Mayo Clin, Rochester, MN USA
[7] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
[8] Univ Illinois, Coll Med, Chicago, IL USA
[9] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[10] Univ Iowa Hosp & Clin, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA
[11] Univ Kansas, Ctr Canc, Westwood, KS USA
[12] Univ Kansas, Kansas City, KS USA
[13] Canc Res Fdn NY, Bronx, NY USA
[14] Univ Kentucky, Lexington, KY USA
[15] Penn Med Abramson Canc Ctr, Philadelphia, PA USA
[16] Johns Hopkins, Sidney Kimmel Canc Ctr, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.4502
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4502
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810
    Appleman, Leonard J.
    Kim, Se Eun
    Harris, Wayne B.
    Pal, Sumanta K.
    Pins, Michael R.
    Kolesar, Jill
    Agarwal, Neeraj
    Parikh, Rahul A.
    Vaena, Daniel A.
    Ryan, Christopher W.
    Hashmi, Mehmood
    Costello, Brian A.
    Cella, David
    Dutcher, Janice P.
    DiPaola, Robert S.
    Haas, Naomi B.
    Wagner, Lynne I.
    Carducci, Michael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17) : 2061 - 2070
  • [2] Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800)
    Carducci, Michael A.
    Manola, Judith
    Nair, Suresh G.
    Liu, Glenn
    Rousey, Steven
    Dutcher, Janice P.
    Wilding, George
    CLINICAL GENITOURINARY CANCER, 2015, 13 (06) : 531 - 539
  • [3] A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
    Mezzanotte-Sharpe, Jessica
    ONeill, Anne
    Mayer, Ingrid A.
    Arteaga, Carlos L.
    Yang, Ximing J.
    Wagner, Lynne I.
    Cella, David
    Meropol, Neal J.
    Alpaugh, R. Katherine
    Saphner, Thomas J.
    Swaney, Robert E.
    Hoelzer, Karen L.
    Gradishar, William J.
    Abramson, Vandana G.
    Sundaram, P. Kothai
    Jilani, Shamim Z.
    Perez, Edith A.
    Lin, Nancy U.
    Jahanzeb, Mohammad
    Wolff, Antonio C.
    Sledge, George W.
    Reid, Sonya A.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, : 275 - 282
  • [4] Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
    Haas, Naomi B.
    Manola, Judith
    Uzzo, Robert G.
    Flaherty, Keith T.
    Wood, Christopher G.
    Kane, Christopher
    Jewett, Michael
    Dutcher, Janice P.
    Atkins, Michael B.
    Pins, Michael
    Wilding, George
    Cella, David
    Wagner, Lynne
    Matin, Surena
    Kuzel, Timothy M.
    Sexton, Wade J.
    Wong, Yu-Ning
    Choueiri, Toni K.
    Pili, Roberto
    Puzanov, Igor
    Kohli, Manish
    Stadler, Walter
    Carducci, Michael
    Coomes, Robert
    DiPaola, Robert S.
    LANCET, 2016, 387 (10032): : 2008 - 2016
  • [5] RENAVIV: A randomized phase III, double-blind, placebo-controlled study of pazopanib with or without abexinostat in patients with locally advanced or metastatic renal cell carcinoma.
    Aggarwal, Rahul Raj
    Thomas, Scott
    Hauke, Ralph J.
    Nordquist, Luke T.
    Munster, Pamela N.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [6] A randomized, double-blind phase III study (VEG105192) of pazopanib (paz) versus placebo (pbo) in patients with advanced/metastatic renal cell carcinoma (mRCC): Updated safety results
    Sternberg, C. N.
    Hawkins, R. E.
    Szczylik, C.
    Davis, I. D.
    Wagstaff, J.
    McCann, L.
    Chen, M.
    Rubin, S. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [7] A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805])
    Pili, Roberto
    Jegede, Opeyemi
    Carducci, Michael A.
    Manola, Judith
    Groteluschen, David L.
    Appleman, Leonard L.
    Liu, Glenn
    Shanks, James C.
    Dakhil, Shaker R.
    Dutcher, Janice
    DiPaola, Robert S.
    CLINICAL GENITOURINARY CANCER, 2017, 15 (06) : 642 - +
  • [8] A randomized phase III study of immune checkpoint inhibition with chemotherapy in treatment-naive metastatic anal cancer patients: A trial of the ECOG-ACRIN cancer research group (EA2176).
    Roth, Marc Thomas
    Catalano, Paul J.
    Ciombor, Kristen Keon
    Benson, Al Bowen
    Yao, Xin
    Yaeger, Rona
    Salem, Mohamed E.
    Morris, Van K.
    Henry, David H.
    Whisenant, Jennifer G.
    O'Dwyer, Peter J.
    Eng, Cathy
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] E2112: Randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group
    Connolly, R.
    Zhao, F.
    Miller, K.
    Tevaarwerk, A.
    Wagner, L.
    Lee, M.
    Murray, J.
    Gray, R.
    Piekarz, R.
    Zujewski, J. A.
    Sparano, J.
    CANCER RESEARCH, 2016, 76
  • [10] RANDOMIZED, DOUBLE-BLIND PHASE III STUDY OF PAZOPANIB IN PATIENTS WITH ADVANCED/METASTATIC RENAL CELL CARCINOMA (MRCC): FINAL OVERALL SURVIVAL (OS) RESULTS
    Sternberg, C. N.
    Hawkins, R. E.
    Szczylik, C.
    Davis, I. D.
    Wagstaff, J.
    McCann, L.
    Chen, M.
    Rubin, S. D.
    ANNALS OF ONCOLOGY, 2010, 21 : 10 - 10
12345